The market for vasopressin early in 2022 is “actually much bigger than we thought,” because of increased COVID hospitalizations, Eagle Pharmaceuticals has learned. The US-based manufacturer launched the first generic version of Endo’s Vasostrict (vasopressin) with 180 days of exclusivity on 18 January.
Eagle Aims To Meet Extra Vasopressin Demand Caused By Covid
Vasopressin Share Expected To Grow; ‘Unknown Is What Happens To Price’
Eagle management provided detailed insight into the existing market for vasopressin, which it entered in January with the first generic version of Endo’s Vasostrict. The US-based player believes operating cash flows for the year, boosted also by its Pemfexy (pemetrexed) launch, could top $170m, paving the way for a major acquisition.
More from Generics
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.